Avantor, Inc.
- Open
- 14.57
- Day high
- 14.59
- Day low
- 14.34
- Prev close
- 14.58
- Volume
- 6.5M
- Mkt cap
- $9.8B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.7
- P/S
- 1.5
- Yield
- —
- Per share
- —
Avantor, Inc. (AVTR) is a Healthcare company listed on NYSE. The stock is up 8% over the past year. Drillr has 1 published research article covering AVTR.
Avantor, Inc. (AVTR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 7 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AVTR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 29, 2026 | $0.19 | $0.21 | +9.4% | $1.7B | +4.9% |
| Apr 29, 2026 | $0.16 | $0.17 | +5.6% | $1.6B | +2.6% |
| Feb 11, 2026 | $0.21 | $0.22 | +4.3% | $1.7B | +6.5% |
| Oct 29, 2025 | $0.23 | $0.22 | -2.7% | $1.6B | -1.4% |
| Aug 1, 2025 | $0.25 | $0.24 | -4.0% | $1.7B | +2.2% |
| Apr 25, 2025 | $0.23 | $0.23 | -0.4% | $1.6B | -1.7% |
| Feb 7, 2025 | $0.25 | $0.27 | +8.4% | $1.7B | +1.4% |
| Oct 25, 2024 | $0.25 | $0.26 | +2.8% | $1.7B | -0.3% |
| Jul 26, 2024 | $0.23 | $0.25 | +7.8% | $1.7B | +0.2% |
| Apr 26, 2024 | $0.20 | $0.22 | +9.5% | $1.7B | -0.1% |
| Feb 14, 2024 | $0.22 | $0.25 | +13.1% | $1.7B | +1.5% |
| Oct 27, 2023 | $0.25 | $0.25 | -0.4% | $1.7B | +0.6% |
AVTR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 20, 2026 | Ligner Emmanueldirector, officer: President and CEO | Tax | 29,803 | $13.33 |
| Aug 18, 2026 | Hankamer Brittanyofficer: EVP, Chief HR Officer | Tax | 181 | $13.66 |
| Aug 4, 2026 | Eck Steven Wofficer: SVP & Chief Accounting Officer | Tax | 1,385 | $13.78 |
| Jul 27, 2026 | Sokenu Claudiusofficer: EVP, Chief Legal & Compliance | Tax | 1,201 | $11.44 |
| Jun 22, 2026 | Walker Coreyofficer: President, VWR Dist. & Servs. | Tax | 3,010 | $9.58 |
| May 11, 2026 | SEVERINO MICHAELdirector | Grant | 25,270 | — |
| May 11, 2026 | Dingemans Simondirector | Grant | 25,270 | — |
| May 11, 2026 | MEHRA SANJEEV Kdirector | Grant | 25,270 | — |
| May 11, 2026 | LUCIER GREGORY Tdirector | Buy | 10,000 | $8.32 |
| May 11, 2026 | SUMME GREGORY Ldirector | Grant | 25,270 | — |
| May 11, 2026 | Makin Louisedirector | Grant | 25,270 | — |
| May 11, 2026 | Murthy Maladirector | Grant | 25,270 | — |
| May 11, 2026 | LUCIER GREGORY Tdirector | Grant | 25,270 | — |
| May 11, 2026 | Massaro Joseph Rdirector | Grant | 25,270 | — |
| May 5, 2026 | Brellier Ludovicofficer: EVP, Bioscience & Medtech | Grant | 246,002 | $8.76 |
Source: AVTR SEC Form 4 filings, latest Aug 20, 2026. For informational purposes only — not investment advice.
See the full AVTR insider & 13F page →Avantor, Inc. company profile
Overview
Avantor, Inc. (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the life sciences and advanced technology industries. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company went public in May 2019. Avantor serves customers across biopharma, healthcare, education and government, advanced technologies, and applied materials industries worldwide. The company has evolved from its origins as a specialty chemicals provider into a comprehensive solutions partner for organizations conducting critical research, development, and production activities.
Business
Avantor operates as a leading supplier of ultra-high-purity materials, customized solutions, and value-added services to customers in life sciences and advanced technology sectors. The company's offerings span the entire product lifecycle from research and development through commercial production. The company operates through two primary business segments following a 2023 reorganization: Laboratory Solutions represents approximately 68% of total revenue and provides materials, consumables, equipment, and services primarily to research laboratories. This segment includes purity chemicals and reagents used in laboratory experiments, lab products and supplies such as glassware and safety equipment, analytical instruments including filtration systems and biological safety cabinets, and education products for academic institutions. The segment serves pharmaceutical and biotech research facilities, academic institutions, government laboratories, and industrial research centers. Bioscience Production accounts for roughly 32% of revenue and focuses on supporting commercial-scale manufacturing in the life sciences industry. Within this segment, bioprocessing represents about two-thirds of the revenue and includes single-use assemblies, process chromatography resins and columns, and specialized equipment for biopharmaceutical manufacturing. The segment also encompasses biomaterials for drug formulation and advanced technology materials for semiconductor and other high-tech manufacturing applications. The company's product portfolio includes over 300,000 products ranging from basic laboratory chemicals to complex custom-engineered solutions. Avantor's materials are used in critical applications where purity, consistency, and regulatory compliance are paramount, such as drug development, vaccine production, gene therapy manufacturing, and semiconductor fabrication.
Revenue model
Avantor generates revenue primarily through direct product sales to end customers, with additional income from value-added services and custom manufacturing solutions. The company's customers include large pharmaceutical companies, biotech firms, academic research institutions, government agencies, and advanced technology manufacturers who purchase products for their research, development, and production activities. The business model centers on providing essential materials and services that customers cannot easily substitute or delay purchasing. Revenue streams include: 1. Product sales of consumables, chemicals, and equipment that require regular replenishment, 2. Custom manufacturing services for specialized materials and single-use assemblies, 3. On-site services including laboratory management and procurement solutions, and 4. Equipment sales and related maintenance services. Several factors influence the company's profitability margins. Positive margin drivers include the mission-critical nature of products that allows for premium pricing, long-term customer relationships that provide pricing stability, operational efficiency improvements through automation and process optimization, and the shift toward higher-margin bioproduction solutions as the biotech industry grows. Conversely, margin pressures arise from raw material cost inflation, competitive intensity in commodity laboratory products, customer inventory destocking cycles that reduce order volumes, wage inflation in manufacturing and distribution operations, and potential tariff impacts on products sourced from international suppliers. The company's cost transformation initiatives, targeting $400 million in annual run-rate savings by 2027, aim to offset inflationary pressures and improve operational efficiency. Pricing strategies are implemented to pass through cost increases, though there can be timing lags between cost inflation and price realization.
Competitive moat
Avantor's competitive moat derives from several interconnected factors, though the strength varies across different product categories and customer segments. The company benefits from high switching costs in mission-critical applications where customers are reluctant to change suppliers due to regulatory requirements, quality validation processes, and the risk of production disruptions. This is particularly strong in biopharmaceutical manufacturing where any supplier change requires extensive requalification. The breadth of Avantor's product portfolio creates customer stickiness through one-stop shopping convenience and integrated procurement relationships. Large pharmaceutical customers often prefer to consolidate suppliers to reduce complexity and ensure consistent quality across their operations. The company's global manufacturing and distribution network provides supply chain reliability that is highly valued by customers operating in regulated industries. However, the moat faces several challenges. In basic laboratory consumables, products are often commoditized with limited differentiation, leading to price-based competition. The company competes against both large multinational competitors like Thermo Fisher Scientific and Merck KGaA, as well as smaller specialized suppliers who may offer more competitive pricing or innovative solutions in niche areas. The emergence of direct-to-customer models and digital marketplaces is increasing price transparency and potentially reducing customer loyalty. Additionally, some large pharmaceutical customers are developing internal capabilities or seeking to diversify their supplier base to reduce dependency on any single provider. While Avantor maintains a solid competitive position through its scale, customer relationships, and operational capabilities, the moat is moderate rather than exceptionally strong, requiring continuous investment in innovation, customer service, and operational efficiency to maintain market position.
Risks & safety
Avantor presents a moderate margin of safety with manageable financial risks but some valuation concerns. • Liquidity and Solvency: Current ratio of 1.12 indicates tight but adequate short-term liquidity. Cash position of $316 million provides limited buffer. Debt-to-equity ratio of 0.67 shows moderate leverage that has improved from previous years through active debt reduction efforts. • Cash Generation: Free cash flow of $81 million in Q1 2025 represents a significant decline from $692 million for full year 2024, indicating potential seasonal patterns or operational challenges. Operating cash flow of $109 million shows positive but modest cash generation. • Valuation Metrics: Trading at 43x trailing P/E ratio appears expensive relative to earnings, though this may reflect temporary earnings depression. EV/EBITDA of 15.5x is reasonable for a specialty chemicals company. Price-to-book ratio of 1.81x suggests modest premium to tangible assets. • Other Considerations: Company is actively reducing leverage and targeting improved margins through cost transformation initiatives. However, recent CEO transition announcement adds management uncertainty. Revenue growth has been challenged with recent organic declines, though bioprocessing segment shows recovery signs.
Recent development
Over the past few years, Avantor has undergone significant strategic transformation focused on portfolio optimization, operational efficiency, and market positioning. The company completed a major business segment reorganization in 2023, consolidating from multiple segments into two primary divisions: Laboratory Solutions and Bioscience Production, providing clearer focus on core markets. A major strategic initiative has been the comprehensive cost transformation program, which was expanded from an initial $300 million target to $400 million in annual run-rate savings by 2027. This program encompasses digital enhancements, pricing optimization, supply chain improvements, and operational streamlining. The company achieved over $130 million in savings during 2024 and is targeting an additional $75 million in 2025. Portfolio rationalization has been another key focus, with the divestiture of the clinical services business for $500 million in 2024, allowing management to concentrate on higher-margin core operations. The company has also strengthened its product portfolio through strategic distribution agreements with companies like Abcam, Fuji Film, and Merck KGaA, expanding its offerings without significant capital investment. Infrastructure investments have included opening new manufacturing facilities in Poland and Singapore, establishing an innovation center in Bridgewater, New Jersey, and launching a customer service center in Mexico. These investments support both geographic expansion and enhanced customer service capabilities. The company has prioritized debt reduction, paying down over $1.3 billion in debt during 2024 and reducing net leverage from nearly 4x to 3.2x. This deleveraging effort has improved financial flexibility while maintaining investment in growth initiatives. Leadership transition is underway with CEO Michael Stubblefield announcing his planned departure once a successor is identified, representing a significant change in executive leadership.
AVTR company profile · for informational purposes only — not investment advice.
Track AVTR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free